Personalised Medicine at Humeltis

Personalised Medicine at Humeltis

Helping you make personal decisions when it comes to cancer treatment

Current treatment guidelines offer very limited assistance exactly which chemotherapeutic drugs to choose for a specific patient
Therefore the majority of therapies are sub-optimal resulting in avoidable fatalities – should personalised diagnostics be available
Humeltis developed an advanced tissue engineering technology that can predict the clinical efficacy of chemotherapeutic drugs based on in vitro methods

How it works

The entire process takes only 5 days and Humeltis can test:
  • Any monotherapy
  • Any combination therapy
  • Even immunotherapies

The technology behind it

The process is scaffold-free, where multiple human lung cell types placed in 3D culture condition produce their own scaffold system and form the required tissue. Once the differentiated cells have been through a sufficient period of growth, they are placed into the 3D tissue microenvironment to re-differentiate -usually within 24 hours (Figure 1). At this point, the primary cells begin to undergo several changes that lead to the formation of an in vitro tissue structure that closely matches that of the lung in vivo, including:

Completely human based

- Only differentiated primary human pulmonary cells are used

No stem cells, no iPS

- Therefore cells differentiate faster into the required pulmonary tissue.


- There is no need for added scaffold as the composition of the culture ensures that the cells themselves produce the natural saffold they grow on.

Markers resemble the primary human lung

- Cytoskeleton arrangement (Figure 2), surfactant production, increased E and decreased N cadherin levels. Also, drastically reduced inflammatory cytokine production.

Immune system

- The unique features of the technology allow cellular components of the immune system to be added and therefore mimic the responses of the human lung more closely.

Ongoing clinical trial

Clinical setup

  • Patients suffering from any kind of pulmonary cancer enrolled
  • Cancer specimen obtained via surgery, biopsy or thoracocentesis
  • Staging
  • Therapy selected and initiated according to threatment guidelines
  • RECIST (Response Evaluation Criteria of Solid Tumours) status recorded after two cycles

Laboratory setup

  • Cancer specimen processed according to Humeltis' method within 24 hours upon intervention
  • Preparations frozen and kept at -80 ℃
  • Once therapy is selected, cells are thawed, 3D aggregates are created and the in vitro treatment with the same medicines as used by clinicians are applied to aggregates
  • Aggregates are incubated for ~48 hours
  • Readiut: viability of cells compared to controls (treated with solvents only) after ~48 hours

Interim trial status & results


  • 210 patients enrolled
  • 92 patients finished the trial
  • 27 patients received chemotherapy
  • 118 patients awaiting results

Interim trial status & results

100%Positive Predictive Value
88%Negative Predictive Value
  • 100% of all the chemotherapy agents that Humeltis’ method predicted to be effective were in fact effective (elicited Complete Response or Partial Response according to the RECIST classification system)
  • 88% of all the chemotherapy agents that Humeltis’ method predicted to be non-effective were in fact non-effective (elicited Stable Disease or Progressive Disease according to the RECIST classification system)
  • 89% of all predictions were correct

RECIST (Response Evaluation Criteria in Solid Tumours)

A set of published rules to objectively evaluate treatment response in solid tumours:

Complete/partial response (CR/PR):
tumour improved (decreased by more than 30% in the sum of the longest diameter)
Progressive disease (PD):
tumour worsened (increased by more than 20% in the sum of the longest diameter)
Stable disease (SD):
tumour stayed the same (Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease)


© 2014-2020 Humeltis